Abraham E, Laterre PF, Garg R et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1322 Bernard GR, Vincent JL, Laterre PF et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699 Bodmann KF, Vogel F (2001) Antimikrobielle Therapie der

Sepsis. Chemother J 10:43 Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644 Camussi G, Albano E, Tetta C et al (1991) The molecular action of tumor necrosis factor-a. Eur J Biochem 202:3 Cooper MS, Stewart PM (2003) Current concepts: Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348: 727

Dellinger RP (2003) Inflammation and coagulation: implications for the septic patient. Clin Infect Dis 36:1259 Dinarello CA (1984) Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 311:1413 Evans TW (2001) Hemodynamic and metabolic therapy in critically ill patients. N Engl J Med 345:1417 Gerard C (2003) Complement C5a in the sepsis syndrome - too much of a good thing? N Engl J Med 348:167 Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA (2006) The Sanford guide to antimicrobial therapy 2006, 36th edn. Antimicrobial Therapy Inc., Sperryville, VA, USA, p 44 Gogos CA, Drosou E, Bassaris HP et al (2000) Pro-versus antiinflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181:176 Hamrahian AH, Oseni TS, Arafah BM (2004) Measurement of serum free cortisol in critically ill patients. N Engl J Med 350:1629

Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138 Liles WC (1997) Apoptosis - role in infection and inflammation. Curr Opin Infect Dis 10:165 Matthay MA (2001) Severe sepsis - a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 344:759

Opal SM, Garber GE, La Rosa SP et al (2003) Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 37:50 Parrillo JE (2005) Severe sepsis andtherapy with activated protein C. N Engl J Med 353:1398 Reinhart K, Hüttemann E, Meier-Hellmann A (2004) Sepsis. In: Burchardi H, Larsen R, Schuster H-P, Suter PM (eds) Die Intensivmedizin. Springer Berlin Heidelberg New York, p851

Rhen T, Cidlowski JA (2005) Anti-inflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 353:1711

Rivers E, Nguyen B, Havstad S et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368 Russel JA (2006) Management ofsepsis.N EnglJMed355:1699 Van Amersfoort ES, Van Berkel TJC, Kuiper J (2003) Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16:379 Van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359

Wilson M, Seymour R, Henderson B (1998) Bacterial perturbation of cytokine networks. Infect Immun 66:2401

Was this article helpful?

0 0

Post a comment